Final results from the IFCT-GFPC 0502 phase III study: maintenance therapy in advanced NSCLC with either Gemcitabine (G) or Erlotinib (E) versus  observation (O) after cisplatin-gemcitabine induction chemotherapy (CT), with a predefined

[pdf]Poster ESMO 2010_IFCT-GFPC 05-02 – M. Perol et al.[/pdf]